Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ATIC | P31939 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10480000 | 0.74 | SMN1; SMN2 (0.36) | KMT2ASMN1; SMN2MEN1ALDH1A1KDM4E | |
| SCHEMBL14980104 | 0.73 | CYP2A6 (0.36) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL619830 | 0.70 | TDP1 (0.62) | KMT2ASMN1; SMN2MEN1GAAPAX8 | |
| SCHEMBL2773204 | 0.70 | TDP1 (0.54) | KMT2ASMN1; SMN2MEN1GAAPAX8 | |
| Bromide SCHEMBL11815117 | 0.69 | TDP1 (0.60) | KMT2ASMN1; SMN2MEN1GAAPAX8 | |
| SCHEMBL29401720 | 0.68 | TDP1 (0.52) | KMT2ASMN1; SMN2MEN1GAAPAX8 | |
| Hydrochloric Acid SCHEMBL27643164 | 0.68 | TDP1 (0.52) | KMT2ASMN1; SMN2MEN1GAAPAX8 | |
| SCHEMBL12946391 | 0.68 | CYP2A6 (0.32) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL29532913 | 0.67 | CYP1A2 (0.43) | KMT2ASMN1; SMN2MEN1GAAPAX8 | |
| SCHEMBL27306171 | 0.67 | CYP1A2 (0.43) | KMT2ASMN1; SMN2MEN1GAAPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501769-B2 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110082170-A1 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-07 | — | — | US | disclosed |
| US-7875627-B2 | e.g.1-(4-Chloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea; 2-Methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethylsulfanyl-benzyl ester; controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1824860-A2 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2006063178-A2 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-0292051-A2 | Thienopyridine derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148843-A1 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | TRPV1, GPR55, P2RX6 | KMT2A 3656/4885SMN1; SMN2 3069/4885MEN1 4696/4885 |
| US-20110082170-A1 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | TRPV1, GPR55, P2RX6 | KMT2A 3656/4885SMN1; SMN2 3069/4885MEN1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.